TG Therapeutics TGTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's retained earnings?
- TG Therapeutics (TGTX) reported retained earnings of -$1.06B in Q1 2026.
- How has TG Therapeutics's retained earnings changed year-over-year?
- TG Therapeutics's retained earnings increased by 30.3% year-over-year, from -$1.52B to -$1.06B.
- What is the long-term trend for TG Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), TG Therapeutics's retained earnings has grown at a 2.0% compound annual growth rate (CAGR), from -$980.6M to -$1.08B.
- What does retained earnings mean?
- The total historical profits the company has kept to reinvest in its operations.
- How do you interpret retained earnings?
- Growth indicates consistent profitability and successful reinvestment, while a decline may signal losses or dividend payouts.
- How does retained earnings compare across companies?
- Often negative for pre-commercial or early-stage biotech companies due to heavy R&D spending exceeding revenue.